EP
PLX icon

Essential Partners’s Protalix BioTherapeutics PLX Stock Holding History

Essential Partners’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$33 Sell
12
-69
-85% -$172 ﹤0.01% 2799
2026
Q2 		$189 Buy
81
+55
+212% +$116 ﹤0.01% 2650
2026
Q1 		$56 Buy
+26
New +$65 ﹤0.01% 2778

Other funds holding PLX

Concurrent Investment Advisors
Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return
Bailard
Bailard Foster City, California $4.94B AUM 25.15% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
TD Waterhouse Canada
TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $540M AUM 34.92% 1-Year Est. Return

Essential Partners's PLX Position: Q3 2026 in Review

Essential Partners reduced its Protalix BioTherapeutics (PLX) stake by 85% in Q3 2026, selling an estimated $172 and leaving 12 shares worth $33. The position accounts for ﹤0.01% of the portfolio, ranked #2799.

Essential Partners first reported a position in PLX in Q1 2026 and has held it in 3 quarters since. The position peaked at $189 in Q2 2026. 9 funds tracked by Wall St. Rank hold PLX as of Q3 2026.

  • Essential Partners held 12 shares of Protalix BioTherapeutics worth $33 as of Q3 2026.
  • Essential Partners sold 69 Protalix BioTherapeutics shares in Q3 2026, an estimated $172.
  • Protalix BioTherapeutics made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2799 holding.
  • Essential Partners first reported a position in Protalix BioTherapeutics in Q1 2026 and has held it in 3 quarters since.
  • Essential Partners's Protalix BioTherapeutics position peaked at $189 in Q2 2026.
  • 9 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.